Evidence map›Paper›PMID 27246703›Full record

ArticleBMC cardiovascular disorders2016

Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.

Freja Stoltze Gaborit, Helle Bosselmann, Caroline Kistorp, Kasper Iversen, Thomas Kumler, Finn Gustafsson, Jens P Goetze, György Sölétormos, Niels Tønder, Morten Schou

Open access · goldAbstract read
In one paragraph

Article in BMC cardiovascular disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Association of suPAR, ST2, and galectin-3 with eGFR decline and mortality in patients with advanced heart failure with reduced ejection fraction.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Freja Stoltze GaboritDepartment of Cardiology, Herlev University Hospital, Herlev, Denmark. freja.stoltze.gaborit@regionh.dk.
Helle BosselmannDepartment of Internal Medicine KNEA, North Zealand University Hospital, Hillerod, Denmark.
Caroline KistorpDepartment of Internal Medicine, Endocrinology Unit, Herlev University Hospital, Herlev, Denmark.
Kasper IversenDepartment of Cardiology, Herlev University Hospital, Herlev, Denmark.
Thomas KumlerDepartment of Cardiology, Herlev University Hospital, Herlev, Denmark.
Finn GustafssonDepartment of Cardiology, Rigshospitalet, Copenhagen, Denmark.
Jens P GoetzeDepartment of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
György SölétormosDepartment of Clinical Biochemistry, North Zealand University Hospital, Hillerod, Denmark.
Niels TønderDepartment of Internal Medicine KNEA, North Zealand University Hospital, Hillerod, Denmark.
Morten SchouDepartment of Cardiology, Herlev University Hospital, Herlev, Denmark.
Herlev Hospital · DKRigshospitalet · DKZealand University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGalectin 3 (Gal-3) reflects cardiac fibrosis in heart failure HF, but has also been associated to renal fibrosis and impaired renal function. Previous research has suggested that Gal-3 could be a cardio-renal biomarker, but it has never been tested simultaneous in a single study whether Gal-3 reflects echocardiographic measures, neurohumoral activity and renal function. The aim of this study was to evaluate the relationship between plasma concentrations of Gal-3 and neurohumoral activity, myocardial and renal function in patients with HF, including advanced echocardiographic measures and 24-h urinary albumin excretion (albuminuria).

methodsWe prospectively enrolled 132 patients with reduced left ventricular ejection fraction (LVEF) referred to an outpatient HF clinic. The patients had a median age of 70 years (interquartile rage: 64-75), 26.5 % were female, median LVEF was 33 % (27-39 %) and 30 % were in NYHA class III-IV.

resultsPatients with plasma concentrations of Gal-3 above the median had significantly lower estimated glomerular filtration rate (eGFR) and this association remained significant in multivariate regression analysis (β: -0.010; 95 % CI -0.012--0.008; P < 0.001), adjusted for age, gender, medical treatment. Plasma concentrations of Gal-3 were not associated with albuminuria (Beta: 0.008; 95 % CI:-0.028-0.045; P = 0.652). There were no association between plasma concentrations of Gal-3 and myocardial function or structure estimated by LVEF, LVmassIndex, LVIDd, E/é or LV global longitudinal strain (P > 0.05 for all). In multivariate analyses plasma concentrations of Gal-3 were significantly associated with the cardiac biomarkers: NT-proBNP (β: 0.047; 95 % CI: 0.008-0.086; P = 0.020), proANP (β: 0.137; 95 % CI: 0.067-0.207; P < 0.001), chromogranin A (β: 0.123; 95 % CI: 0.052-0.194; P < 0.001) and Copeptin (β: 0.080; 95 % CI: 0.000-0.160; P = 0.049). Multivariate analysis was adjusted for eGFR, age, gender and medical treatment.

conclusionsIncreased plasma concentrations of Gal-3 are associated with reduced eGFR and increased plasma concentrations of NT-proBNP, proANP, chromogranin A and Copeptin, but not with echocardiographic parameters reflecting myocardial function. These results suggest that Gal-3 reflects both increased neurohumoral activity and reduced eGFR, but not myocardial function in patients with systolic HF.

Indexed as

Echocardiography, Doppler, PulsedGlomerular Filtration RateOutpatientsAgedAlbuminuriaAtrial Natriuretic FactorBiomarkersBlood ProteinsChi-Square DistributionChromogranin AFemaleGalectin 3GalectinsGlycopeptidesHeart FailureHumansAtrial Natriuretic FactorBiomarkersBlood ProteinsCHGA protein, humanChromogranin AcopeptinsGalectin 3GalectinsGlycopeptidesLGALS3 protein, humanNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)EchocardiographyGalectin 3Heart failure reduced ejection fractionNatriuretic peptidesRenal function

Identifiers

PMID27246703
PMCPMC4886419
OpenAlexW2412724424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.